Recent FDA approval of two new targeted therapies, Glasdegib, a Hedgehog pathway inhibitor (Norsworthy et al., 2019) and Venetoclax, a selective BCL-2 inhibitor (Guerra et al., 2019), for elderly AML patients have been granted. Here, BCL2 is linked to acute myeloid leukemia.